Cargando…

Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)

BACKGROUND: Novel and effective immunotherapies are required for refractory or recurrent sarcomas. Transforming growth factor-beta (TGF-β) is a diverse regulatory and fibrogenic protein expressed in multiple sarcoma tumors that promotes epithelial-mesenchymal transition and excessive deposition of e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Lu, Liang, Xin, Xu, Jie, Sun, Xin, Liu, Kuisheng, Sun, Kunkun, Li, Yuan, Tang, Xiaodong, Li, Xianan, Zhan, Xing, Niu, Xiaohui, Guo, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503089/ https://www.ncbi.nlm.nih.gov/pubmed/37715133 http://dx.doi.org/10.1186/s12885-023-11390-4

Ejemplares similares

Codex Bodley, 2858
Publicado: (1960)

Générateur déclenche: MPS 2858
por: BaillocL, JM
Publicado: (1967)

Interpretación del Códice Bodley 2858
por: Caso, Alfonso, 1896-1970
Publicado: (1960)

A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer
por: Wang, Jiayu, et al.
Publicado: (2023)

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis
por: Zhou, Jun, et al.
Publicado: (2023)

Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
por: Liu, Jiayong, et al.
Publicado: (2022)

Anemia and hemodilution: analysis of a single center cohort based on 2,858 red cell mass measurements
por: Drevon, Louis, et al.
Publicado: (2021)

Exploring regression dilution bias using repeat measurements of 2858 variables in ≤49 000 UK Biobank participants
por: Rutter, Charlotte E, et al.
Publicado: (2023)

P953: PHASE I STUDY OF TQB3602 CAPSULE, AN ORAL PROTEASOME INHIBITOR, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Tang, W., et al.
Publicado: (2022)

Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial
por: Lan, Chun-Yan, et al.
Publicado: (2022)

Reassessing the pathogenicity of c.2858G>T(p.(G953V)) in COL4A5 Gene: report of 19 Chinese families
por: Zhang, Yanqin, et al.
Publicado: (2019)

Second generation androgen receptor antagonist, TQB3720 abrogates prostate cancer growth via AR/GPX4 axis activated ferroptosis
por: Zhang, Zhongqing, et al.
Publicado: (2023)

circ_2858 Helps Blood-Brain Barrier Disruption by Increasing VEGFA via Sponging miR-93-5p during Escherichia coli Meningitis
por: Yang, Ruicheng, et al.
Publicado: (2020)

Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2023)

Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two‐Cohort, Phase Ib/II Trial
por: Xu, Jie, et al.
Publicado: (2021)

Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02)
por: Dong, Sen, et al.
Publicado: (2021)

Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858]
por: Lai, Fangfang, et al.
Publicado: (2023)

Osteosarcoma (Osteogenic sarcoma)
por: Picci, Piero
Publicado: (2007)

Studies of an alveolar soft tissue sarcoma.
por: Udekwu, F. A., et al.
Publicado: (1965)

Alveolar soft part sarcoma of the forearm
por: Asokan, B., et al.
Publicado: (2017)

Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma
por: Evola, Francesco R., et al.
Publicado: (2017)

Alveolar soft part sarcoma of the right calf: A case report
por: Wang, Bin, et al.
Publicado: (2020)

Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
por: Xie, Lu, et al.
Publicado: (2021)

Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy
por: Xu, Jie, et al.
Publicado: (2022)

Primary Alveolar Soft Part Sarcoma of the Lung
por: Kim, Yeong Dae, et al.
Publicado: (2007)

Primary Alveolar Soft Part Sarcoma of the Scapula
por: Yavuz, Alpaslan, et al.
Publicado: (2013)

Alveolar soft part sarcoma of flexure tendon
por: Pruksapong, Chatchai, et al.
Publicado: (2017)

Alveolar soft part sarcoma with brain metastases
por: Perumall, Vinodh Vayara, et al.
Publicado: (2017)

Alveolar Soft Part Sarcoma of the Tongue in an Adolescent
por: Suárez, Amaranto, et al.
Publicado: (2020)

The current management of alveolar soft part sarcomas
por: Chang, Xiaojing, et al.
Publicado: (2021)

Abnormalities of the FHIT Transcripts in Osteosarcoma and Ewing Sarcoma
por: Hinohara, Shin‐ichi, et al.
Publicado: (1998)

Complete remission of metastatic osteosarcoma using combined modality therapy: a retrospective analysis of unselected patients in China
por: Xie, Lu, et al.
Publicado: (2021)

PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
por: Zheng, Bingxin, et al.
Publicado: (2018)

Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
por: Liu, Kuisheng, et al.
Publicado: (2017)

A Case of Alveolar Soft Part Sarcoma of the Pleura
por: Ju, Hyeong Uk, et al.
Publicado: (2013)

Alveolar Soft Part Sarcoma: A Rare Diagnosis
por: Sarkar, Priyanka, et al.
Publicado: (2013)

Pediatric Primary Alveolar Soft Part Sarcoma of the Bladder
por: Tanabe, Kazuya, et al.
Publicado: (2018)

An atypical presentation of alveolar soft part sarcoma of tongue
por: Chopra, Neha, et al.
Publicado: (2017)

Advanced alveolar soft part sarcoma responds to apatinib
por: Zhou, Yong, et al.
Publicado: (2017)

Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing’s sarcoma
por: Dai, Xing, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_86qrpjet4jlrksud0rhk00cbjf